History of outcome measures for myasthenia gravis

Muscle and Nerve

Volumn 42, Issue 1, 2010, Pages 5-13

  Burns, Ted M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

MG composite; MG QOL15; Myasthenia gravis; Outcome measures; Rating scales

Indexed keywords

AZATHIOPRINE; CORTICOTROPIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; STEROID;

CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; ENDURANCE; FUNCTIONAL ASSESSMENT; HISTORY; HUMAN; MORTALITY; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; SELF REPORT; STRENGTH; SYMPTOM; TREATMENT OUTCOME;

HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; STEROIDS; TREATMENT OUTCOME;

EID: 77954130816     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21713     Document Type: Review

References (94)

1. Erb W. Zur casuistic der bulbären Lähmungen. Arch Psychiat 1879; 9:325.
2. Wilks S. On cerebritis, hysteria, and bulbar paralysis, as illustrative of arrest of function of the cerebro-spinal centres. Guy's Hosp Rep 1877;22:7.
3. Simon HE. Myasthenia gravis. Effect of treatment with anterior pituitary extract: preliminary report. JAMA 1935;104:2065-2066.
4. Kennedy FS, Moersch FP. Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and the early part of 1932. Can Med Assoc J 1937;216-223.
5. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;1200-1201.
6. Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939;110:544-561.
7. Torda C, Wolff HG. Effects of adrenocorticotrophic hormone on neuromuscular function in patients with myasthenia gravis. J Clin Invest 1949;28:1228-1235.
8. Shy GM, Brendler S, Rabinovitch R, McEachern D. Effects of cortisone in certain neuromuscular disorders. JAMA 1950;144:1353-1358.
9. Schlezinger NS. Present status of therapy in myasthenia gravis. JAMA 1952;148:508-513.
10. Millikan CH, Eaton LM. Clinical evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1951;1:145-152.
11. Grob D. Course and management of myasthenia gravis. JAMA 1953; 153:529-532.
12. Freydberg LD. The place of corticotropin in the treatment of myasthenia gravis. Ann Intern Med 1960;52:806-816.
13. Von Reis G, Liljestrand A, Matell G. Results with ACTH and spironolactone in severe cases of myasthenia gravis. Acta Neurol Scand 1965;41(S13)463-471.
14. Grob D, Namba T. Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses. JAMA 1966;198:703-707.
15. Griggs RC, McFarlin DE, Engel WK. Severe occult juvenile myasthenia gravis responsive to long-term corticosteroid therapy. Trans Am Neurol Assoc 1968;93:216-218.
16. Cape CA, Utterback RA. Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment. J Neurol Neurosurg Psychiatry 1969;32:290-296.
17. Cape CA, Utterback RA. Long-term maintenance ACTH therapy in myasthenia gravis. Neurology 1971;21:411-412.
18. Johns TR, Crowley WJ, Miller JQ et al. The syndrome of myasthenia and polymyositis with comments on therapy. Ann N Y Acad Sci 1971; 183:64-71.
19. Jenkins RB. Treatment of myasthenia gravis with prednisone. Lancet 1972;1:765-767.
20. Brunner NG, Namba T, Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology 1972;22:603-610.
21. Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20.
22. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974;290:81-84.
23. Howard FM, Duane DD, Lambert EH, Daube JR. Alternate-day prednisone: preliminary report of a double-blind controlled study. Annals N Y Acad Sci 1976;274:596-607.
24. Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976;26:729-740.
25. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505:472-499.
26. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment in myasthenia gravis: report of 116 cases. Ann Neurol 1984;15: 291-298. (Pubitemid 14164748)
27. Grob D. Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
28. McEachern D. The thymus in relation to myasthenia gravis. Medicine 1943;22:1-20.
29. Keynes G. The results of thymectomy in myasthenia gravis. Br Med J 1949;2:611-616.
30. Eaton LM, Claggett OT. Thymectomy in the treatment of myasthenia gravis. JAMA 1950;142:963-967.
31. Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission (spontaneous and following thymectomy). JAMA 1953;153:1270-1273.
32. Eaton LM, Claggett OT. Present status of thymectomy in treatment of myasthenia gravis. Am J Med 1955;19:703-717.
33. Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 1966;16:431-439.
34. Mantegazza R, Antozzi C, Pelucchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453. (Pubitemid 18262976)
35. Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990;237:339-344.
36. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 1991;106:213-220.
37. Osserman KE, Kornfeld P, Cohen E, Genkins G, Mendelow H, Goldberg H, et al. Studies in myasthenia gravis. Review of two hundred eighty-two cases at The Mount Sinai Hospital, New York City. AMA Arch Intern Med 1958;102:72-81.
38. Simpson JA. An evaluation of thymectomy in myasthenia gravis. Brain 1958;81:112-144.
39. Henson RA, Stern GM, Thompson VC. Thymectomy for myasthenia gravis. Brain 1965;88:11-28.
40. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969;2: 321-339.
41. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. for the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55: 16-23.
42. Maggi L, Andreetta F, Antozzi C, Baggi F, Bernasconi P, Cavalcante P, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol 2008;201-202:237-244.
43. Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AchR-antibody positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010 (in press).
44. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 1997;150: 59-62.
45. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T; Japanese FK 506 MG Study Group. Clinical study of FK506 in patients with myasthnia gravis. Muscle Nerve 2003;28:570-574.
46. Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, et al. The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol 2010;257:98-102.
47. Raggi A, Leonardi M, Mantegazza R, Casale S, Fioravanti G. Social support and self-efficacy in patients with myasthenia gravis: a common pathway towards positive health outcomes. Neurological Sciences, 2010, 31, 2, 231-235, 10.1007/s10072009-0194-8.
48. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-444. (Pubitemid 37194196)
49. Oosterhuis HJGH. Studies in myasthenia gravis. Part 1. A clinical study of 180 patients. J Neurol Sci 1964;1:512-546.
50. Oosterhuis HJGH. Myasthenia gravis. A review. Clin Neurol Neurosurg 1981;83:105-135.
51. Spector PE. Summated rating scale construction; an introduction. Thousand Oaks, CA: Sage Publications; 1991.
52. Besinger UA, Toyka KV, Heninger K, Fateh-Moghadam A, Schumm F, Sandel P, et al. Long-term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann N Y Acad Sci 1981;377:812-815.
53. Besinger UA, Toyka KV, Hömberg M, Heninger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33: 1316-1321. (Pubitemid 13021194)
54. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242.
55. Tindall RSA, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724. (Pubitemid 17036477)
56. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551. (Pubitemid 23233874)
57. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-772. (Pubitemid 28362935)
58. Barohn RJ. Standards of measurement in myasthenia gravis. Ann N Y Acad Sci 2003;998:432-439.
59. Zinman L, Bril V. IVIG treatment for myasthenia gravis. Effectiveness, limitations, and novel therapeutic strategies. Ann N Y Acad Sci 2008;1132:264-270.
60. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64: 1968-1970. (Pubitemid 40800720)
61. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335-1341.
62. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-796. (Pubitemid 27249184)
63. Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;247:286-290.
64. Gajdos P, Sharshar T, Chevret S. Standards of measurements in myasthenia gravis. Ann N Y Acad Sci 2003;998:445-452.
65. Gajdos P, Chevret S. Treatment of myastenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci 2008; 1132:271-275.
66. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52: 1487-1489.
67. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394-399.
68. Wolfe GI, Barohn RJ, Sanders DB, McDermott MP, and Muscle Study Group. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve 2008;38:1429-1433.
69. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129:1481-1492.
70. Burns TM, Conaway MR, Cutter GR, Sanders DB. The construction of an efficient evaluative instrument for myasthenia gravis: the MG Composite. Muscle Nerve 2008;38:1553-1562.
71. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
72. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99. (Pubitemid 32059659)
73. Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 2008;47:731-736. (Pubitemid 351936221)
74. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to actylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307:769-775.
75. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular disease. Neurology 2001;56:94-96. (Pubitemid 32059658)
76. Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001;22:363-369.
77. Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C, et al. Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci 2002;23:59-68.
78. Padua L, Galassi G, Ariatti A, Aprile I, Caliandro P, Evoli A, et al. Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci 2005;25:331-336.
79. Rostedt A, Padua L, Sta?lberg EV. Validation of the Swedish version of the disease-specific myasthenia gravis questionnaire. Neurol Sci 2006;27:91-96. (Pubitemid 43983244)
80. Burns TM, Conaway MR, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010 [accepted for publication].
81. Palace J, Newsom-Davis J, Lecky B; Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
82. Bullinger J, Verbinnen R, De Boever S, et al. Indices versus profiles: advantages and disadvantages. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer Academic; 1993.
83. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology 1990;4:29-38.
84. Hanestad B. Errors of measurement affecting the reliability and validity of data acquired from self-assessed quality of life. Scand J Caring Sci 1990;4:29-33.
85. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001;24:512-516. (Pubitemid 32246787)
86. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051-1057. (Pubitemid 46569141)
87. Seyedsadjadi R, Lipscomb B, Weinman J, Rose M, Sanders DB. Quality of life in myasthenia gravis. Neurology 2009;72:A468 (Abstract).
88. Mullins LL, Carpentier MY, Paul RH, Sanders DB; Muscle Study Group. A disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008;38:947-956.
89. Burns TM, Conaway M, Cutter G, Sanders DB; Muscle Study Group. Less is more, or almost as much. The development of a fifteen-item quality-of-life instrument for patients with myasthenia gravis. Muscle Nerve 2008;38:957-963.
90. Burns TM, Grouse CK, Conaway MR, Sanders DB; MG Composite and MG-QOL15 Study Group. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve [Epub ahead of print].
91. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis. An analysis of efficacy, safety, and tolerability. Neurology 2003;61: 1438-1440.
92. Ponsetti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone- dependent myasthenia gravis. Neurology 2005;64:1641-1643. (Pubitemid 40617711)
93. Aban IB, Wolfe GI, Cutter GC, Kaminski HJ, Jaretzki A, Minisman G, et al.; Advisory Committee. The MGTX experience. Challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol 2008;201-202:80-84.
94. Barohn RJ, Pasnoor M, Herbelin L, Burns TM, Dimachkie M; Methotrexate Study Group. Methotrexate in the treatment of myasthenia gravis. International Conference on Myasthenia Gravis, Paris, France. December, 2009:81.